Chronic aspergillus infections of the respiratory tract: Diagnosis, management and antifungal resistance

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 584-589

  Izumikawa, Koichi ^a   Takazono, Takahiro ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

aspergilloma; azole resistance; CCPA; CNPA

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTIFICIAL EMBOLISM; ASPERGILLOMA; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BRONCHIAL ARTERY; CHRONIC DISEASE; COUGHING; DISEASE ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; LUNG ASPERGILLOSIS; LUNG LAVAGE; REVIEW; SPUTUM; SPUTUM CULTURE; SURVIVAL RATE; TRANSBRONCHIAL BIOPSY; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTIFUNGAL AGENTS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; HUMANS; PULMONARY ASPERGILLOSIS;

EID: 78349311018     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833ed694     Document Type: Review

References (71)

1. Binder RE, Faling LJ, Pugatch RD, et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 1982; 61: 109-124.
2. Gefter WB, Weingrad TR, Epstein DM, et al. "Semi-invasive" pulmonary aspergillosis: a new look at the spectrum of Aspergillus infections of the lung. Radiology 1981; 140:313-321.
3. Yousem SA. The histological spectrum of chronic necrotizing forms of pulmonary aspergillosis. Hum Pathol 1997; 28:650-656.
4. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 (Suppl 3):S265-280.
5. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110:685-692.
6. Sakkour A, WangT,Tashkin D. A 56-year-old woman with COPD and multiple pulmonary nodules. Chest 2008; 133:566-569.
7. Du H, Huang W. Chronic necrotizing pulmonary aspergillosis or invasive pulmonary aspergillosis. Chest 2009; 136:1189-1190.
8. Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7 (Suppl 2):25-31.
9. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43 (Suppl 1):S207-238.
10. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360.
11. Riscili BP, Wood KL. Noninvasive pulmonary Aspergillus infections. Clin Chest Med 2009; 30:315-335; vii.
12. Denning DW. Aspergillosis. Hasrrison's principles of internal medicine, New York, U.S.A.: McGraw-Hill Companies; 2008. pp. 1256-1260.
13. Crosdale DJ, Poulton KV, Ollier WE, et al. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J Infect Dis 2001; 184:653-656.
14. Vaid M, Kaur S, Sambatakou H, et al. Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med 2007; 45:183-186.
15. Carvalho A, Cunha C, Pasqualotto AC, et al. Genetic variability of innate immunity impacts human susceptibility to fungal diseases. Int J Infect Dis 2010; 14:e460-e468.
16. Carvalho A, Pasqualotto AC, Pitzurra L, et al. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008; 197:618-621.
17. Daly RC, Pairolero PC, Piehler JM, et al. Pulmonary aspergilloma. Results of surgical treatment. J Thorac Cardiovasc Surg 1986; 92:981-988.
18. Campbell MJ, Clayton YM. Bronchopulmonary aspergillosis. A correlation of the clinical and laboratory findings in 272 patients investigated for bronchopulmonary aspergillosis. Am Rev Respir Dis 1964; 89:186-196.
19. Soltanzadeh H, Wychulis AR, Sadr F, et al. Surgical treatment of pulmonary aspergilloma. Ann Surg 1977; 186:13-16.
20. Hedayati MT, Pasqualotto AC, Warn PA, et al. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007; 153:1677-1692.
21. Pasqualotto AC, Denning DW. An aspergilloma caused by Aspergillus flavus. Med Mycol 2008; 46:275-278.
22. Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol 2009; 47 (Suppl 1):S261-270.
23. Balajee SA, Gribskov JL, Hanley E, et al. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 2005; 4:625-632.
24. Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49:102-111.
25. Sugui JA, Vinh DC, Nardone G, et al. Neosartorya udagawae (Aspergillus udagawae), an emerging agent of aspergillosis: how different is it from Aspergillus fumigatus? J Clin Microbiol 2009; 48:220-228.
26. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, et al. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 2008; 52:1244-1251.
27. Saraceno JL, Phelps DT, Ferro TJ, et al. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997; 112:541-548.
28. Shah R, Vaideeswar P, Pandit SP. Pathology of pulmonary aspergillomas. Indian J Pathol Microbiol 2008; 51:342-345.
29. Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis, including simple aspergilloma. Eur Respir J 2010 (express published online).
30. Franquet T, Gimenez A, Cremades R, et al. Spontaneous reversibility of 'pleural thickening' in a patient with semi-invasive pulmonary aspergillosis: radiographic and CT findings. Eur Radiol 2000; 10:722-724.
31. Kim SY, Lee KS, Han J, et al. Semiinvasive pulmonary aspergillosis: CT and pathologic findings in six patients. AJR Am J Roentgenol 2000; 174:795-798.
32. Nam HS, Jeon K, Um SW, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2010; 14:e479-e482.
33. Zmeili OS, Soubani AO. Pulmonary aspergillosis: a clinical update. QJM 2007; 100:317-334.
34. Kitasato Y,Tao Y, HoshinoT, et al. Comparison ofAspergillusgalactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology 2009; 14:701-708.
35. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-1427.
36. Parra I, Remacha A, Rezusta A, et al. Chronic necrotizing pulmonary aspergillosis. Med Mycol 2004; 42:369-371.
37. Sugino K, Hasegawa C, Sano G, et al. Pathophysiological study of chronic necrotizing pulmonary aspergillosis. Jpn J Infect Dis 2008; 61:450-453.
38. Regnard JF, Icard P, Nicolosi M, et al. Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg 2000; 69:898-903.
39. Kim YT, Kang MC, SungSW, Kim JH. Good long-term outcomes after surgical treatment of simple and complex pulmonary aspergilloma. Ann Thorac Surg 2005; 79:294-298.
40. Brik A, Salem AM, Kamal AR, et al. Surgical outcome of pulmonary aspergilloma. Eur J Cardiothorac Surg 2008; 34:882-885.
41. De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988; 31:476-485.
42. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23:607-614.
43. Tsubura E. Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group. Kekkaku 1997; 72:557-564.
44. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treat-mentofchronic cavitary pulmonaryaspergillosis.JInfect 2006; 52:e133-1e37.
45. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006; 119:527e517-527e524.
46. Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007; 131:1435-1441.
47. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-359.
48. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-347.
49. Lewis RE. Pharmacodynamic implications for use of antifungal agents. Curr Opin Pharmacol 2007; 7:491-497.
50. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21:580-586.
51. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211.
52. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24-34.
53. Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009; 49:928-930.
54. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36:372-379.
55. Izumikawa K, Ohtsu Y, Kawabata M, et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 2007; 45:273-278.
56. Kohno S, Izumikawa K, Ogawa K., et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infection 2010; (in press).
57. Kelleher P, Goodsall A, Mulgirigama A, et al. Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 2006; 27:1307-1310.
58. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PloS Med 2008; 5:e219.
59. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resi stance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12:141-147.
60. Howard SJ, Pasqualotto AC, Denning DW. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 2009; 16:683-688.
61. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15:1068-1076.
62. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41:1364-1368.
63. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. Document M38-A2. Clinical Laboratory Standards Institute, Wayne, PA; 2008.
64. EUCAST. Technical Note on the method forthe determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008; 14:982-984.
65. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52:2468-2472.
66. Cowen LE, Steinbach WJ. Stress, drugs and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 2008; 7:747-764.
67. Verweij PE, Snelders E, Kema GH, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009; 9:789-795.
68. Snelders E, Huis In 't Veld RA, Rijs AJ, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009; 75:4053-4057.
69. Chen J, Li H, Li R, et al. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother 2005; 55:31-37.
70. Bellete B, Raberin H, Morel J, et al. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med Mycol 2010; 48:197-200.
71. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50:917-921.